Pfizer Inc. (PFE) |
| 27.16 0.055 (0.2%) 02-26 09:35 |
| Open: | 27.09 |
| High: | 27.27 |
| Low: | 27.09 |
| Volume: | 1,332,212 |
| Market Cap: | 154,424(M) |
| PE Ratio: | 19.97 |
| Exchange: | New York Stock Exchange |
| Industry: | Drug Manufacturers - General |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 32.63 |
| Resistance 1: | 27.94 |
| Pivot price: | 27.16 |
| Support 1: | 26.10 |
| Support 2: | 24.96 |
| 52w High: | 27.94 |
| 52w Low: | 20.92 |
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
| EPS | 1.360 |
| Book Value | 16.320 |
| PEG Ratio | 0.00 |
| Gross Profit | 8.337 |
| Profit Margin (%) | 12.42 |
| Operating Margin (%) | 24.63 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 8.6 |
Wed, 25 Feb 2026
RBC Capital Initiates Pfizer (PFE) with $25 Target, Warns of Structural Revenue Headwinds - Insider Monkey
Wed, 25 Feb 2026
Pfizer (PFE) Receives "Underperform" Rating from RBC Capital | P - GuruFocus
Wed, 25 Feb 2026
Pfizer Stock: Is PFE Underperforming the Healthcare Sector? - Barchart.com
Wed, 25 Feb 2026
Where is Pfizer Inc. (PFE) headed? - MSN
Tue, 24 Feb 2026
Pfizer wins full FDA approval for Braftovi (PFE:NYSE) - Seeking Alpha
Mon, 23 Feb 2026
Pfizer, Inc. (PFE) Stock Analysis: A Glimpse into Potential 7.18% Upside with Robust Dividend Yield - DirectorsTalk Interviews
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |